

Tirzepatide/Cyanocobalamin

ACTIVE Tirzepatide + vitamin B12
FORM Injectable; catalog says all doses; concentration not listed

01 / TREATMENT OVERVIEW

The clinical and commercial fit

Substantial average weight reduction when tirzepatide is paired with nutrition and physical-activity support. Reduced hunger, earlier fullness, and improved control over food intake. A weekly formulation may offer a convenient, high-impact option for patients who have not achieved durable results with lifestyle measures alone.

WHY PRACTITIONERS CONSIDER IT

Substantial average weight reduction when tirzepatide is paired with nutrition and physical-activity support.

A weekly formulation may offer a convenient, high-impact option for patients who have not achieved durable results with lifestyle measures alone.

02 / TREATMENT FEATURES

01 Administration Catalog format: Injectable; catalog says all doses; concentration not listed. The prescribing clinician and dispensing pharmacy confirm the exact preparation, concentration, handling, and administration technique.	02 Typical frequency The studied tirzepatide regimen is once weekly with gradual escalation. The exact blend schedule is prescription-specific.
03 Expected duration Treatment is generally long term while benefit, tolerability, and clinical need continue.	04 Practical advantages A weekly formulation may offer a convenient, high-impact option for patients who have not achieved durable results with lifestyle measures alone.

03 / PATIENT BENEFITS

Why suitable patients may consider it

POTENTIAL PATIENT BENEFITS

What suitable patients may value

- Substantial average weight reduction when tirzepatide is paired with nutrition and physical-activity support.
- Reduced hunger, earlier fullness, and improved control over food intake.
- Potential improvements in waist size, blood sugar, blood pressure, physical function, and other obesity-related measures.

ADDITIONAL PATIENT VALUE

Experience and care goals

- A weekly formulation may offer a convenient, high-impact option for patients who have not achieved durable results with lifestyle measures alone.
- Added vitamin B12 may support patients with a documented or clinically plausible deficiency.

Benefits are based primarily on standardized tirzepatide injection. Results vary, are not guaranteed, and the exact compounded vitamin blend requires separate clinical and quality review.

04 / IDEAL CLIENT PROFILE

Who is most likely to be a fit

BEST-FIT PATIENT

Qualification profile

- A carefully screened adult whose goals align with the potential benefits above and who understands that individual response varies.
- A patient willing to complete clinician-directed baseline review, monitoring, and an outcome-based follow-up plan.

CLINICAL CONTEXT

Qualification notes

- A weekly formulation may offer a convenient, high-impact option for patients who have not achieved durable results with lifestyle measures alone.
- Strongest fit occurs when the exact formulation, route, source, contraindications, and measurable goals can be clearly documented.

05 / POTENTIAL SIDE EFFECTS

The safety information patients need

COMMON OR TEMPORARY

Expected tolerability issues

- Nausea, diarrhea, constipation, vomiting, abdominal discomfort, reflux, and injection-site reactions are the most practical tolerability issues.
- Symptoms are often most noticeable during dose escalation and may improve with time.

SERIOUS OR IMPORTANT

Risks that change the decision

- Important risks include pancreatitis, gallbladder disease, dehydration-related kidney injury, severe gastrointestinal reactions, and serious hypersensitivity.
- Low blood sugar is mainly a concern with insulin or insulin-releasing diabetes medicines.
- The product carries a boxed warning based on thyroid C-cell tumors in rodents and is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.

06 / CONTRAINDICATIONS

Who may not be a suitable candidate

AVOID OR USE SPECIALIST INPUT

Suitability limits

- Pregnancy or an active plan to become pregnant.
- Personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2.
- Prior serious hypersensitivity to the active drug or formulation ingredients.

Side effects and suitability notes are not exhaustive. The exact product, patient history, dosing, monitoring, and emergency guidance require review by an appropriately licensed clinician.

What to check before treatment

BEFORE TREATMENT

Screening checklist

- Confirm BMI, weight-related conditions, prior weight-care attempts, current medicines, and realistic long-term goals.
- Review diabetes therapy, low-blood-sugar risk, kidney function when clinically indicated, and any history of pancreatitis or gallbladder disease.
- Ask about severe delayed stomach emptying, persistent vomiting, planned surgery or deep sedation, pregnancy potential, and thyroid-cancer history.

ESCALATION

When to refer

- Urgent medical assessment is appropriate for severe or persistent abdominal pain, repeated vomiting with dehydration, suspected gallbladder disease, serious allergic reaction, or symptoms of marked hypoglycemia.
- Complex diabetes regimens, active eating disorders, pregnancy, severe gastrointestinal disease, or uncertain endocrine cancer history require appropriately qualified medical review.

Screening and referral decisions are patient-specific. This summary does not replace diagnosis, prescribing information, informed consent, or local clinical requirements.

What the strongest public sources support

CURRENT STATUS

Tirzepatide injection is approved for chronic weight management in defined adults and for moderate to severe obstructive sleep apnea in adults with obesity. This exact compounded vitamin blend was not used in the pivotal trials.

- SURMOUNT-1 randomized 2,539 adults without diabetes. Mean weight change at 72 weeks was about -15.0%, -19.5%, and -20.9% across the 5 mg, 10 mg, and 15 mg groups versus -3.1% with placebo. The trial did not test the added vitamin.

KEY CLINICAL SOURCES

Primary or official source: Zepbound prescribing information, FDA, January 2026

Primary or official source: SURMOUNT-1 tirzepatide obesity trial, NEJM 2022

Evidence and regulatory status can change. Confirm the current label, formulation, route, dose, pharmacy source, jurisdiction, and intended use before offering treatment.

How the research maps to this exact product

Weekly tirzepatide caused about 15.0% to 20.9% mean weight loss at 72 weeks, versus 3.1% with placebo, in 2,539 adults. The exact tirzepatide+vitamin B12 mix has not been tested in a large trial.

STUDY 01

Primary human finding

- SURMOUNT-1 - double-blind RCT; 2,539 adults with overweight/obesity and no diabetes; tirzepatide 5, 10, or 15 mg under the skin weekly plus lifestyle care for 72 weeks. Mean weight change: -15.0%, -19.5%, and -20.9% vs -3.1% placebo. GI effects were most common. Match: main peptide and injection match, but the added vitamin and catalog concentration do not.

STUDY 02

Supporting context

- No peer-reviewed human trial was located for the exact tirzepatide plus vitamin B12 compounded formula. Evidence for vitamin replacement does not show extra weight loss in people without a deficiency.

Research on a related ingredient, route, dose, or population may not predict the outcome of the exact product offered. Potential benefits remain patient-specific and are not guaranteed.

What people report and how the evidence matches

REAL-WORLD REPORTS

What people describe

- In about 12 detailed injection accounts sampled, reduced hunger sometimes began after the first dose but often took several weeks. Strong loss and no-effect stories both appeared. Nausea, constipation, fatigue, burping, and hair loss during rapid loss were common themes. Reports did not isolate a benefit from added vitamin B12.

TIMING AND MATCH

When changes are reported

- Users often say appetite changes start in days to 4 weeks. Weight change is judged over months.
- Direct evidence is for the branded peptide alone at fixed trial doses, not this compounded vitamin blend.

SOURCE NOTES

Direct links are included for verification. Public personal accounts are unverified and cannot show how common an outcome is. Evidence for one ingredient, route, or dose does not automatically validate a different compounded or blended product.

Product listing: Lennox catalog page; accessed Aug 26, 2026

User-reported evidence: Tirzepatide side-effect discussion, Reddit 2025

User-reported evidence: Non-response discussion, Reddit 2024

PRACTICE NOTE

This report supports informed discussion; it does not tell anyone to start, stop, or dose a treatment. Verify the exact ingredients, concentration, route, dispensing source, storage, beyond-use date, contraindications, and monitoring plan.